98%
921
2 minutes
20
The prognosis and outcome of treatment for chronic hepatitis B virus (HBV) infection are predicted by levels of HBV DNA in serum. These levels are composed of relaxed circular DNA (rcDNA) and double stranded linear DNA in viral particles, whereas, HBV DNA in liver tissue also can be covalently closed circular DNA (cccDNA) or integrated into the human genome. The aim of this study was to investigate the quantitative relation between HBV DNA in serum and tissue, its change over time and how these markers relate to serum levels of hepatitis B surface antigen (HBsAg). Serum and liver biopsies taken from 15 patients with chronic HBV infection on two occasions during 2.7-11.1 years were analyzed retrospectively. At baseline, the median HBV DNA levels in serum were 7.76 log IU/mL in nine hepatitis B e antigen (HBeAg) positive and 3.65 log IU/mL in six HBeAg-negative patients. At follow-up, serum HBV DNA, serum HBsAg, and intrahepatic HBV DNA (ihDNA) levels had declined by 4.36, 0.52, and 1.47 log units, respectively, in seven patients that lost HBeAg, whereas the corresponding reductions were 0.36, 0.30, and 0.39 log units in eight patients with unchanged HBeAg status. We conclude that HBV DNA in liver tissue declined almost 1000 times less than HBV DNA in serum during and after loss of HBeAg. This finding raises the possibility that integrated sequences constitute a significant part of the ihDNA. Alternatively, the greater decline of HBV DNA in serum might be due to yet unknown mechanisms acting downstream of reverse transcription.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jmv.24841 | DOI Listing |
Microbiol Spectr
September 2025
The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
Hepatitis B virus (HBV) infection remains a major global health burden. While interferon-alpha (IFNα) therapy demonstrates antiviral and immunomodulatory effects, reliable prognostic markers for sustained response are needed. Transaminases, hematological parameters, and cytokines may serve as potential predictors, but their dynamic changes during IFNα therapy remain poorly characterized.
View Article and Find Full Text PDFFront Cell Infect Microbiol
September 2025
Core Facility of the First Hospital of Jilin University, Changchun, Jilin, China.
Diabetes and viral hepatitis, particularly hepatitis B (HBV) and hepatitis C (HCV), are significant global health burdens with complex interconnections. This review discusses the molecular mechanisms linking viral hepatitis to diabetes, focusing on inflammatory pathways, oxidative stress, and epigenetic modifications. Key findings highlight the role of STAT3 in promoting insulin resistance and β-cell apoptosis, the impact of ER stress and NOX-mediated oxidative stress on metabolic dysfunction, and the influence of epigenetic changes such as DNA methylation and histone acetylation on glucose homeostasis.
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
September 2025
French National Reference Center for Hepatitis B, C and delta Viruses, Department of Virology, Hôpital Henri Mondor, Créteil, France; INSERM U955, Créteil, France. Electronic address:
Measurement of hepatitis B virus (HBV) DNA levels is the standard of care for diagnosis active HBV infection, assessing disease severity and prognosis, and guiding treatment decisions and monitoring response to therapy. In the study, the analytical and clinical performance of the ELITe InGenius System for quantifying HBV DNA was evaluated. A total of 377 of archived EDTA plasma or serum specimens were tested.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
The Third Clinical Medical College, Qingdao University School of Medicine, Qingdao Municipal Hospital, Qingdao, Shandong, China.
Introduction: Oral nucleos(t)ide analogues (NAs) are widely used in managing hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Among first-line therapies, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are commonly prescribed. However, their comparative efficacy and safety remain unclear in HBV-ACLF.
View Article and Find Full Text PDFMedicine (Baltimore)
August 2025
Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
Nucleos(t)ide analogues (NAs) have demonstrated potent efficacy in suppressing viral replication in chronic hepatitis B (CHB). This 48-week study compared the efficacy and safety of NA treatment for CHB patients with high viral load (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] > 7 log10 IU/mL). This retrospective study included 180 nucleos(t)ide-naïve CHB patients with high viral load undergoing NA monotherapy, which were stratified into 3 groups: entecavir (ETV, n = 82), tenofovir disoproxil fumarate (TDF, n = 58), and tenofovir alafenamide fumarate (TAF, n = 40).
View Article and Find Full Text PDF